ImmunoCellular Therapeutics Appoints Anthony J. Gringeri, PhD, as Senior Vice President, Strategic Resources

ImmunoCellular Therapeutics

today announced that Anthony J. Gringeri, PhD, has been appointed Senior Vice President, Strategic Resources, reporting to Andrew Gengos, Chief Executive Officer. In this newly created leadership position, Dr. Gringeri will bring his wide range of expertise to bear on key functions, including project management, clinical development, regulatory affairs, business development, stakeholder relations and strategic planning. “Tony joins ImmunoCellular at an important and exciting juncture on our path toward building a leading cancer immunotherapy company,” said CEO Andrew Gengos. “With the prospect of three active clinical programs by early 2014, including the possibility of embarking on a registration program for our lead ICT-107 program, we need to supplement our already strong management team with additional capacity and skill sets. Tony's deep and broad US and EU pharmaceutical experience will be invaluable to achieving our aspiration to build a commercial enterprise serving patients in major markets.” Dr. Gringeri brings more than 25 years of executive experience in the pharmaceutical and biotechnology industry to ImmunoCellular, having successfully led multiple functions and cross-functional teams throughout his career, including in the areas of clinical, regulatory and commercial planning and operations, finance, licensing and alliance management. He joins ImmunoCellular from ViaCyte, where he was Vice President and Chief Development Officer, responsible for all preclinical, clinical and regulatory activities. Previously, Dr. Gringeri served as Chief Operating Officer for Amsterdam Molecular Therapeutics, responsible for corporate strategy and operations, business development, building the company's commercial capability, and playing a key role in its initial public offering. Dr. Gringeri worked with Amgen for 15 years in a series of executive leadership roles. He served as Vice President, Product Development, Executive Director, Scientific Operations, Vice President, Scientific Outreach and Licensing Operations, and Vice President, Project Management & Strategic Planning. Dr. Gringeri was the Product Development Team Leader responsible for the successful development and commercialization of ARANESP® (darbepoetin alfa), to treat anemia in patients with kidney failure as well as cancer patients. Dr. Gringeri holds a Master's degree and a PhD in pharmacology from the University of Rochester, and has authored multiple scientific publications. About ImmunoCellular Therapeutics, Ltd. ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com. Forward-Looking Statements for ImmunoCellular Therapeutics This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully developed or commercialized. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.